Literature DB >> 26757906

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Qiang Li1, Aditya Bagrodia1, Eugene K Cha1, Jonathan A Coleman2,3.   

Abstract

Urothelial carcinoma is a highly heterogeneous disease that can arise throughout the entire urothelial lining from the renal pelvis to the proximal urethra. Upper tract urothelial carcinoma (UTUC) is rare, and while it shares many similarities with urothelial carcinoma of bladder (UCB), there are also significant differences between UTUC and UCB regarding clinical management and outcomes. No major advances have been made recently in the development of new systemic therapies for urothelial carcinoma, partly due to the lack of understanding of underlying molecular pathogenetic mechanisms. In the past decade, the emergence of next-generation sequencing has greatly enabled genomic characterization of tumor samples. Researchers are currently exploring a personalized approach to augment traditional clinical decision-making based on genetic alterations. In the present review, we summarize current genomic advances in UTUC and discuss the potential implications of these developments for developing prognostic and predictive biomarkers.

Entities:  

Keywords:  Biomarkers; Genomics; Prediction; Upper tract urothelial carcinoma

Mesh:

Year:  2016        PMID: 26757906      PMCID: PMC4823991          DOI: 10.1007/s11934-015-0566-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  55 in total

Review 1.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 2.  Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Authors:  Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2015-03-05       Impact factor: 2.872

3.  Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival.

Authors:  A Rey; P C Lara; E Redondo; E Valdés; R Apolinario
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

4.  Modulation of mismatch repair and genomic stability by miR-155.

Authors:  Nicola Valeri; Pierluigi Gasparini; Muller Fabbri; Chiara Braconi; Angelo Veronese; Francesca Lovat; Brett Adair; Ivan Vannini; Francesca Fanini; Arianna Bottoni; Stefan Costinean; Sukhinder K Sandhu; Gerard J Nuovo; Hansjuerg Alder; Roberta Gafa; Federica Calore; Manuela Ferracin; Giovanni Lanza; Stefano Volinia; Massimo Negrini; Michael A McIlhatton; Dino Amadori; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  Comparative genomic hybridization analysis of transitional cell carcinomas of the renal pelvis.

Authors:  M A Rigola; C Fuster; C Casadevall; M Bernués; M R Caballín; A Gelabert; J Egozcue; R Miró
Journal:  Cancer Genet Cytogenet       Date:  2001-05

6.  European guidelines on upper tract urothelial carcinomas: 2013 update.

Authors:  Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-03-19       Impact factor: 20.096

Review 7.  The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Authors:  Steven C Smith; Alexander S Baras; Jae K Lee; Dan Theodorescu
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

8.  Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma.

Authors:  Gengyan Xiong; Jin Liu; Qi Tang; Yu Fan; Dong Fang; Kaiwei Yang; Feng Xie; Min Zhang; Lei Zhang; Libo Liu; Cuijian Zhang; Lin Yao; Li Yang; Weimin Ci; Wei Zhao; Yanqing Gong; Qun He; Kan Gong; Zhisong He; Gang Wang; Xuesong Li; Yinglu Guo; Liqun Zhou
Journal:  Epigenomics       Date:  2015-04-27       Impact factor: 4.778

9.  FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

Authors:  Johanna M M van Oers; Ellen C Zwarthoff; Ishtiaq Rehman; Abdel-Rahmene Azzouzi; Olivier Cussenot; Mark Meuth; Freddie C Hamdy; James W F Catto
Journal:  Eur Urol       Date:  2008-06-13       Impact factor: 20.096

10.  Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.

Authors:  Song Wu; Jiahao Chen; Pei Dong; Shiqiang Zhang; Yingying He; Liang Sun; Jialou Zhu; Yanbing Cheng; Xianxin Li; Aifa Tang; Yi Huang; Yaoting Gui; Chunxiao Liu; Guosheng Yang; Fangjian Zhou; Zhiming Cai; Rongfu Wang
Journal:  BMC Cancer       Date:  2014-11-18       Impact factor: 4.430

View more
  11 in total

1.  Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.

Authors:  Yue Wang; Jinxia Zhang; Yunfan Wang; Shufang Wang; Yu Zhang; Qi Miao; Fei Gao; Huiying He
Journal:  Front Med       Date:  2019-04-24       Impact factor: 4.592

Review 2.  Developing Precision Medicine for Bladder Cancer.

Authors:  Brendan J Guercio; Gopa Iyer; Jonathan E Rosenberg
Journal:  Hematol Oncol Clin North Am       Date:  2021-04-10       Impact factor: 2.861

Review 3.  Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.

Authors:  Maria Frantzi; Antonia Vlahou
Journal:  Bladder Cancer       Date:  2017-01-27

4.  Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Jiwei Huang; Yanqing Wang; Yichu Yuan; YongHui Chen; Wen Kong; Haige Chen; Jin Zhang; Yiran Huang
Journal:  Oncotarget       Date:  2017-05-30

5.  Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma.

Authors:  Jiwei Huang; Yichu Yuan; Yanqing Wang; Jin Zhang; Wen Kong; Haige Chen; Yonghui Chen; Yiran Huang
Journal:  Oncotarget       Date:  2017-05-30

6.  STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma.

Authors:  Kyosuke Matsuzaki; Kazutoshi Fujita; Yujiro Hayashi; Makoto Matsushita; Satoshi Nojima; Kentaro Jingushi; Taigo Kato; Atsunari Kawashima; Takeshi Ujike; Akira Nagahara; Motohide Uemura; Ryoichi Imamura; Seiji Yamaguchi; Hiroaki Fushimi; Hiroshi Miyamoto; Eiichi Morii; Norio Nonomura
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

Review 7.  Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.

Authors:  Vadim S Koshkin; Appledene S Osbourne; Petros Grivas
Journal:  Transl Androl Urol       Date:  2021-10

8.  Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.

Authors:  Songbai Wang; Mike Burgess; Christopher Major; Alistair English; Maranna Sweeney; Arndt Hartmann
Journal:  J Pathol Clin Res       Date:  2020-04-18

Review 9.  Current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma.

Authors:  Hoon Choi; Jae Young Park; Jae Hyun Bae; Bum Sik Tae
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

10.  Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program.

Authors:  Fernando Sabino M Monteiro; Adriano Gonçalves E Silva; Andrea Juliana P de S Gomes; Carolina Dutra; Naira Oliveira Ferreira; Rodrigo Coutinho Mariano; Fabio A Schutz
Journal:  Ther Adv Med Oncol       Date:  2021-05-18       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.